Claims for Patent: 10,478,497

✉ Email this page to a colleague

Summary for Patent: 10,478,497

Title:	Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
Abstract:	The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
Inventor(s):	Benjamin; Susan (Chatillon, FR), Planquette; Cecile (Palaiseau, FR), Delansorne; Remi (Paris, FR)
Assignee:	HYBRIGENICS S.A. (Paris, FR)
Application Number:	15/655,394
Patent Claims:	1. The combination of inecalcitol with an anti-CD38 agent, wherein said anti-CD38 agent is selected from the group consisting of daratumumab, isatuximab, and MOR202.

Details for Patent 10,478,497

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	DARZALEX	daratumumab	Injection	761036	November 16, 2015	⤷ Subscribe	2039-12-05
Sanofi-aventis U.s. Llc	SARCLISA	isatuximab-irfc	Injection	761113	March 02, 2020	⤷ Subscribe	2039-12-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.